Skip to Main Content
Welcome to the Marketplace

Go to Main Navigation


BAY u9773

Cayman Chemical

Thumbnail image


  • Inchi: InChI=1S/C27H36O5S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-25(24(28)15-14-17-26(29)30)33-23-20-18-22(19-21-23)27(31)32/h6-7,9-13,16,18-21,24-25,28H,2-5,8,14-15,17H2,1H3,(H,29,30)(H,31,32)/b7-6-,10-9-,12-11+,16-13+/t24-,25+/m0/s1
  • Purity: ≥95%
  • Raptas: Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Leukotrienes||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Immunology & Inflammation|Pulmonary Diseases|Asthma||Research Area|Lipid Biochemistry|Lipoxygenase Pathways||Research Area|Neuroscience|Seizure Disorders
  • Smiles: CCCCC/C=C\C\C=C/C=C\C=C/[C@@H](Sc1ccc(cc1)C(=O)O)C(O)CCCC(=O)O
  • Cas Number: 154978-38-8
  • Formulation: A solution in ethanol
  • Storage Temp: -80
  • Shipping Temp: -80
  • Formula Markup: C27H36O5S
  • Formula Weight: 472.6
  • Shelf Life Days: 365


A CysLT1 and CysLT2 receptor antagonist; inhibits LTD4- or LTC4-induced contractions in isolated guinea pig trachea, rat lung, ferret spleen, and sheep bronchus (pA2s = 6.8-7.4); suppresses airway hypersensitivity and BALF eosinophil infiltration in a guinea pig model of ovalbumin-induced asthma at 0.1 mg/kg; increases the latency to generalized seizures and decreases the EEG amplitude in a mouse model of PTZ-induced seizures